Most patients we see for pain are on scheduled II opioids. To us it makes sense to start
patients on a safer scheduled III opioid-like buprenorphine, which has a ceiling on …

Objectives To assess the effectiveness and tolerability of buprenorphine for cancer pain in
adults and children. Methods We searched CENTRAL, MEDLINE, EMBASE, ISI Web of …

The article focuses on the use of buprenorphine for the treatment of pain in patients in the
US It states that buprenorphine is a mixed opioid agonist/antagonist formulated with …

Aim The aim of this workshop, is to explores the various use of buprenorphine in treating
acute pain, chronic pain, substance use disorder, palliative care and end of life settings …

In Australia, high-dose sublingual buprenorphine and long-acting injectable buprenorphine
are available. High-dose buprenorphine is used predominantly in the setting of opioid use …

Outcomes 1. Construct low-dose buprenorphine initiation protocols using local formularies
(patch, sublingual, buccal, IV) appropriate for the inpatient setting. 2. Provide education …

Outcomes 1. Describe the shifting buprenorphine policy landscape 2. Discuss the FDA-
approved indications and formulations of buprenorphine, as well as emerging uses of …

Background Buprenorphine is a high affinity partial mu-opioid agonist with increasing use as
an analgesic in patients with serious illness (See Fast Facts# 441), including those with …

Transdermal buprenorphine is a new formulation of the old drug available for the treatment
of cancer and non-cancer pain. The drug offers number of interesting new features and was …

Aim Chronic pain affects 100 million Americans; opioid use disorder affects 3-5 million
Americans. Of those who are prescribed opioids for chronic pain, approximately 10 …